Gamida Cell (NASDAQ: GMDA) is one of 298 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Gamida Cell to similar businesses based on the strength of its dividends, analyst recommendations, risk, profitability, earnings, institutional ownership and valuation.
Institutional & Insider Ownership
1.7% of Gamida Cell shares are owned by institutional investors. Comparatively, 49.7% of shares of all “Biotechnology” companies are owned by institutional investors. 16.5% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares Gamida Cell and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Gamida Cell||N/A||-$52.93 million||-1.09|
|Gamida Cell Competitors||$586.75 million||$105.75 million||-14.95|
Gamida Cell’s competitors have higher revenue and earnings than Gamida Cell. Gamida Cell is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of recent ratings and price targets for Gamida Cell and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Gamida Cell Competitors||722||2615||6961||211||2.63|
Gamida Cell presently has a consensus price target of $19.40, indicating a potential upside of 69.43%. As a group, “Biotechnology” companies have a potential upside of 6.52%. Given Gamida Cell’s stronger consensus rating and higher possible upside, analysts plainly believe Gamida Cell is more favorable than its competitors.
This table compares Gamida Cell and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Gamida Cell Competitors||-3,005.03%||-137.64%||-34.91%|
Gamida Cell beats its competitors on 7 of the 12 factors compared.
About Gamida Cell
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in a patients with high-risk blood cancers, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.